These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 25941160

  • 41. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
    Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, Kahn SE, Marx N, Alexander JH, Zinman B, Pfarr E, Schnaidt S, Meinicke T, von Eynatten M, George JT, Johansen OE, Wanner C, CARMELINA investigators.
    Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
    [Abstract] [Full Text] [Related]

  • 42. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
    Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
    [Abstract] [Full Text] [Related]

  • 43. Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial.
    Sidelmann Christensen A, Storgaard H, Hædersdal S, Hansen T, Knop FK, Vilsbøll T.
    BMJ Open; 2018 Oct 03; 8(10):e022517. PubMed ID: 30287671
    [Abstract] [Full Text] [Related]

  • 44. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.
    BMJ; 2012 Mar 12; 344():e1369. PubMed ID: 22411919
    [Abstract] [Full Text] [Related]

  • 45. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA.
    Diabetes Obes Metab; 2011 Jul 12; 13(7):653-61. PubMed ID: 21410628
    [Abstract] [Full Text] [Related]

  • 46. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Wu W, Li Y, Chen X, Lin D, Xiang S, Shen F, Gu X.
    Med Sci Monit; 2015 Sep 09; 21():2678-84. PubMed ID: 26350766
    [Abstract] [Full Text] [Related]

  • 47. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Deeks ED.
    Drugs; 2012 Sep 10; 72(13):1793-824. PubMed ID: 22913735
    [Abstract] [Full Text] [Related]

  • 48. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
    Mikhail N.
    Postgrad Med; 2012 Jul 10; 124(4):138-44. PubMed ID: 22913902
    [Abstract] [Full Text] [Related]

  • 49. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
    Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J, DINAMO Study Group.
    Lancet Diabetes Endocrinol; 2023 Mar 10; 11(3):169-181. PubMed ID: 36738751
    [Abstract] [Full Text] [Related]

  • 50. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
    Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ.
    Diabetes Care; 2013 Dec 10; 36(12):3875-81. PubMed ID: 24062327
    [Abstract] [Full Text] [Related]

  • 51. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
    Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2014 Nov 10; 16(11):1078-86. PubMed ID: 24865132
    [Abstract] [Full Text] [Related]

  • 52. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
    McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ.
    Diabetes Care; 2013 Feb 10; 36(2):237-44. PubMed ID: 23033241
    [Abstract] [Full Text] [Related]

  • 53. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 10; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 54. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G, Garofolo M, Del Prato S.
    Nutr Metab Cardiovasc Dis; 2016 May 10; 26(5):361-73. PubMed ID: 27105869
    [Abstract] [Full Text] [Related]

  • 55. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH.
    Adv Ther; 2011 Jun 10; 28(6):447-59. PubMed ID: 21603986
    [Abstract] [Full Text] [Related]

  • 56. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
    Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Ouwens DM, Hartmann B, Holst JJ, Touw DJ, Danser AHJ, Joles JA, van Raalte DH.
    Diabetes Care; 2020 Nov 10; 43(11):2889-2893. PubMed ID: 32900785
    [Abstract] [Full Text] [Related]

  • 57. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D, Li L, Liu C.
    Diabetes Obes Metab; 2014 Jan 10; 16(1):30-7. PubMed ID: 23803146
    [Abstract] [Full Text] [Related]

  • 58. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ.
    Diabetes Metab; 2012 Apr 10; 38(2):89-101. PubMed ID: 22197148
    [Abstract] [Full Text] [Related]

  • 59. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.
    Umpierrez GE, Cardona S, Chachkhiani D, Fayfman M, Saiyed S, Wang H, Vellanki P, Haw JS, Olson DE, Pasquel FJ, Johnson TM.
    J Am Med Dir Assoc; 2018 May 10; 19(5):399-404.e3. PubMed ID: 29289540
    [Abstract] [Full Text] [Related]

  • 60. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ.
    Diab Vasc Dis Res; 2015 May 10; 12(3):164-74. PubMed ID: 25780262
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.